Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
farletuzumab + carboplatin + taxane
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Farletuzumab + carboplatin + taxane is a combination chemotherapy regimen investigated for the treatment of platinum-sensitive epithelial ovarian cancer in first relapse. It pairs farletuzumab, a humanized monoclonal antibody that targets folate receptor alpha (FRα), with carboplatin, a platinum-based chemotherapeutic alkylating agent, and a taxane (either paclitaxel or docetaxel), which disrupts cell division by stabilizing microtubules[1][2][3]. Farletuzumab mediates antitumor effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and receptor internalization. Carboplatin induces DNA crosslinking, leading to cancer cell death. Taxanes inhibit microtubule depolymerization, causing mitotic arrest. This regimen was evaluated in a large phase III clinical trial for its efficacy and safety relative to carboplatin/taxane alone in relapsed ovarian cancer, with additional trials in other epithelial cancers[1][2][3].
- Other names
- farletuzumab + carboplatin + taxanefarletuzumab + carboplatin + paclitaxelfarletuzumab + carboplatin + docetaxel
02
Targets
FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on farletuzumab + carboplatin + taxane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on farletuzumab + carboplatin + taxane.